Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder...
Agency Continues to Take Steps to Reduce New Cases of Opioid Use Disorder
The Centers for Disease Control and Prevention (CDC) yesterday released its long-awaited updated Guideline for Prescribing Opioids for Chronic Pain. The American Society of Anesthesiologists (ASA)...